CollPlant Biotechnologies (CLGN) Accumulated Expenses (2018 - 2025)

CollPlant Biotechnologies' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $1.2 million for Q4 2025.

• Quarterly Accumulated Expenses fell 3.55% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 3.55% YoY) and the FY2025 annual result came in at $1.2 million, down 3.55% from the prior year.
• Accumulated Expenses was $1.2 million for Q4 2025 at CollPlant Biotechnologies, up from $1.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $1.7 million in Q1 2024 and bottomed at $957000.0 in Q3 2021.
• A 5-year average of $1.3 million and a median of $1.3 million in 2023 frame the typical range for Accumulated Expenses.
• Peak annual rise in Accumulated Expenses reached 97.62% in 2021, while the deepest fall reached 41.89% in 2021.
• CollPlant Biotechnologies' Accumulated Expenses stood at $1.4 million in 2021, then rose by 0.98% to $1.4 million in 2022, then advanced by 14.14% to $1.6 million in 2023, then dropped by 21.43% to $1.3 million in 2024, then fell by 3.55% to $1.2 million in 2025.
• Business Quant data shows CLGN's Accumulated Expenses at $1.2 million in Q4 2025, $1.2 million in Q3 2025, and $1.3 million in Q2 2025.